Next Article in Journal
Reactions of Polychlorinated Pyrimidines with DABCO
Next Article in Special Issue
Novel One-Pot Synthesis of Methyl 4-Hydroxy-2-thioxo-1,2-dihydroquinoline-3-carboxylate: Synthetic and Crystallographic Studies
Previous Article in Journal
2-{[Bis(propan-2-yl)carbamothioyl]sulfanyl}acetic acid
Previous Article in Special Issue
4-[(3,5-Dimethyl-1H-pyrazol-1-yl)methyl]-4-methyl-2-phenyl-4,5-dihydrooxazole
Open AccessShort Note
Peer-Review Record

3-{[(2,3-Dichlorophenyl)amino]methyl}-5-(furan-2-ylmethylidene)-1,3-thiazolidine-2,4-dione

Molbank 2019, 2019(4), M1083; https://doi.org/10.3390/M1083
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Molbank 2019, 2019(4), M1083; https://doi.org/10.3390/M1083
Received: 16 August 2019 / Revised: 2 September 2019 / Accepted: 3 September 2019 / Published: 3 October 2019
(This article belongs to the Special Issue Heterocycle Reactions)

Round 1

Reviewer 1 Report

The authors describe the synthesis of (E)-3-(((2,3-dichlorophenyl)amino)methyl)-5-(furan-2-2 ylmethylene)thiazolidine-2,4-dione. This compound is new and could be useful for its biological properties (anticancer and anti-inflammatory).
The work is interesting, the presentation adequate and the characterisation of new compound sufficient. Moreover, the medicinal chemistry experiments are clearly described and the results support the conclusions of the authors. Based on that I suggest that the paper is accepted after some minor changes.
Changes:
-Page 1, line 26: Please use past tense.
-Page 1, line 28: Please use ''accounts for 11.6%...''
-Regarding Scheme 1, please add the 2,3-chlorines on the structure instead of using the R group. Moreover, reaction times are missing for steps 2 and 3. The labels should be aligned.
-DOIs are missing from the references.

Author Response

The authors describe the synthesis of (E)-3-(((2,3-Dichlorophenyl)amino)methyl)-5-(furan-2-2 ylmethylene)thiazolidine-2,4-dione. This compound is new and could be useful for its biological properties (anticancer and anti-inflammatory).
The work is interesting, the presentation adequate and the characterisation of new compound sufficient. Moreover, the medicinal chemistry experiments are clearly described and the results support the conclusions of the authors. Based on that I suggest that the paper is accepted after some minor changes.
Changes:
-Page 1, line 26: Please use past tense.

Past tense was used as suggested by the reviewer.

-Page 1, line 28: Please use ''accounts for 11.6%...''

Cancer is a worldwide burden and female breast cancer accounts for 11.6% of the total cancer deaths.

-Regarding Scheme 1, please add the 2,3-chlorines on the structure instead of using the R group. Moreover, reaction times are missing for steps 2 and 3. The labels should be aligned.

The 2,3-dichlorines have been added instead of R group.

-DOIs are missing from the references.

DOI have been added  from the references.

Reviewer 2 Report

Dear Authors,

Manuscript ID: molbank-585490 entitled (E)-3-(((2,3-dichlorophenyl)amino)methyl)-5-(furan-2-ylmethylene)thiazolidine-2,4-dione presents the synthesis, molecular docking study and biological activity of title compound. In my opinion, the paper should be published after minor revision.

Authors should take into account the following comments:

line 2, please correct (E)-3-(((2,3-dichlorophenyl)amino)methyl)-5-(furan-2-ylmethylene)thiazolidine-2,4-dione into (E)-3-(((2,3-Dichlorophenyl)amino)methyl)-5-(furan-2-2 ylmethylene)thiazolidine-2,4-dione please correct μMol into μM and μg/ml into μg/mL in all text line 18, please correct anti-inflammatory into Anti-inflammatory line 46, please correct 2,3-dichloroaniline into 2,3-Dichloroaniline -please add the mobile phase (solvent or solvent mixture) that was used in TLC

-   please assign signals in the 13C NMR spectrum

-   please, improve references carefully according instructions for authors

Author Response

Manuscript ID: molbank-585490 entitled (E)-3-(((2,3-dichlorophenyl)amino)methyl)-5-(furan-2-ylmethylene)thiazolidine-2,4-dione presents the synthesis, molecular docking study and biological activity of title compound. In my opinion, the paper should be published after minor revision.

Authors should take into account the following comments:

line 2, please correct (E)-3-(((2,3-dichlorophenyl)amino)methyl)-5-(furan-2-ylmethylene)thiazolidine-2,4-dione into (E)-3-(((2,3-Dichlorophenyl)amino)methyl)-5-(furan-2-2 ylmethylene)thiazolidine-2,4-dione
please correct μMol into μM and μg/ml into μg/mL in all text
line 18, please correct anti-inflammatory into Anti-inflammatory
line 46, please correct 2,3-dichloroaniline into 2,3-Dichloroaniline
-please add the mobile phase (solvent or solvent mixture) that was used in TLC

(E)-3-(((2,3-Dichlorophenyl)amino)methyl)-5-(furan-2-2 ylmethylene)thiazolidine-2,4-dione

μM and μg/mL were corrected in the text

Anti-inflammatory was corrected in the line 18

The compound’s purity was checked by thin layer chromatography (TLC) on silica coated aluminium sheet (silica gel 60F254) with the help of ethyl acetate and hexane mixtures (1:3).

-   please assign signals in the 13C NMR spectrum

13C NMR (400 MHz, DMSO-d6, δ ppm): 169.3, 165.5, 149.1, 147.9, 143.2, 131.9, 128.4, 119.8, 118.9, 117.4, 116.3, 113.6 and 110.3.

-   please, improve references carefully according instructions for authors

Improved in the resubmitted manuscript.

This manuscript is a resubmission of an earlier submission. The following is a list of the peer review reports and author responses from that submission.


Back to TopTop